ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chronic Myeloid Leukemia (CML)
Blood (2018) 132 (Supplement 1): 1739.
Currently there are no citedby results. Try again later.
